Nilotinib
DANZITEN, Tasigna
Kinase Inhibitor
NADAC/unit
N/A
No Shortage
Tier 1: 84.2%
PA Req: 480.2%
5 Manufacturers
13 ANDAs
Nilotinib targets specific kinase enzymes involved in cancer cell growth and proliferation.
Market Intelligence
2026-03-11 Class III Recall: Cipla USA, Inc.
2026-03-11 Class III Recall: Cipla USA, Inc.
Generic Manufacturers
APOTEX INCAZURITY PHARMACEUTICALS INCDR REDDYS LABORATORIES LTDHETERO LABS LTD UNIT VMSN LABORATORIES PRIVATE LTDNOVARTIS PHARMACEUTICALS CORPTORRENT PHARMACEUTICALS LTD
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.